» Articles » PMID: 33162877

Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis

Overview
Journal Front Neurosci
Date 2020 Nov 9
PMID 33162877
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Antipsychotic medication non-adherence has detrimental effects on patients' clinical outcome. It is unclear which risk factors affect adherence most and which interventions are effective at improving adherence to antipsychotic medication. The aim of this systematic review is to summarize evidence exploring risk factors of non-adherence to antipsychotic treatment and effectiveness of intervention to improve adherence in patients with psychotic spectrum disorders. We conducted a systematic search in PubMed from 1994 to 2019 using a structured search strategy. Studies were quality assessed, and studies reporting on possible risk factors and intervention strategies were synthesized. We reviewed 26 studies on factors related to antipsychotic medication adherence and 17 studies on interventions to improve adherence in patients with psychosis spectrum disorders. Risk factors of non-adherence included younger age, poor illness insight, cannabis abuse, and the presence of severe positive symptoms. Antipsychotic medication adherence was associated with positive attitude toward medication of both patients and their family, family involvement, and illness insight. Somewhat consistent evidence was found for interventions involving family and technology-based interventions and strategies combining depot medication with psychoeducation. However, given the wide range of heterogeneous interventions and methodological limitations, findings must be interpreted with caution. Despite much effort invested in the research area of antipsychotic medication adherence, the heterogeneity in study design and outcome, adding to confounding effects and possible biases, and methodological restraints complicate comparability of the results. Future research in this field should therefore be conducted on patient-tailored interventions, considering risk factors affecting the patient and implementing well-validated, standardized assessment methods. Accordingly, this systematic review seeks to facilitate endeavors improving adherence to antipsychotic treatment by identifying modifiable and non-modifiable risk factors, outlining effective intervention strategies, and proposing recommendations to enhance adherence strategies.

Citing Articles

The profile of long-stay patients in a psychiatric hospital in KwaZulu-Natal, South Africa.

Myeni S, Ntlantsana V, Tomita A, Aguwa U, Bridgmohun R, Shabalala S S Afr J Psychiatr. 2025; 31:2358.

PMID: 39968315 PMC: 11830845. DOI: 10.4102/sajpsychiatry.v31i0.2358.


Antipsychotic medication non-adherence and its determinants among out-patients with schizophrenia.

Erohubie P, Oriji S, Olotu S, Agbonile I, Anozie I, Erohubie O Malawi Med J. 2025; 36(4):288-297.

PMID: 39877526 PMC: 11770358. DOI: 10.4314/mmj.v36i4.8.


Pharmacist-led Si-care (schizophrenia care) model to improve medication adherence and symptom management in schizophrenia.

Cahaya N, Kristina S, Widayanti A, Green J Explor Res Clin Soc Pharm. 2024; 16:100544.

PMID: 39687446 PMC: 11647222. DOI: 10.1016/j.rcsop.2024.100544.


Development and validation of the General attitude towards Medication Questionnaire (GAMQ).

Peerdeman K, Tekampe J, van Middendorp H, van Laarhoven A, Rippe R, Peters M BMC Psychol. 2024; 12(1):632.

PMID: 39511640 PMC: 11542261. DOI: 10.1186/s40359-024-02108-7.


Unidentified genotype does not affect pharmacological treatment for patients with first episode psychosis.

De Brabander E, van Amelsvoort T, van Westrhenen R J Psychopharmacol. 2024; 38(12):1111-1121.

PMID: 39344086 PMC: 11528939. DOI: 10.1177/02698811241279022.


References
1.
Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H . A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2012; 39(5):999-1007. PMC: 3756784. DOI: 10.1093/schbul/sbs116. View

2.
Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S . Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3):241-7. DOI: 10.1001/archpsyc.56.3.241. View

3.
Higashi K, Medic G, Littlewood K, Diez T, Granstrom O, De Hert M . Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013; 3(4):200-18. PMC: 3805432. DOI: 10.1177/2045125312474019. View

4.
Goff D, Hill M, Freudenreich O . Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010; 71 Suppl 2:20-6. DOI: 10.4088/JCP.9096su1cc.04. View

5.
Morken G, Grawe R, Widen J . Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. J Clin Psychiatry. 2007; 68(4):566-71. DOI: 10.4088/jcp.v68n0409. View